CompletedNot Applicable

Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France

France22,500 participantsStarted 2012-01-01

Plain-language summary

Evaluation of the following prognostic factors in France, based on national quotation data: volume per center, patient age, geographic distance from a clinical center, delay for chemotherapy,Upfront surgery.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * \- Diagnosic of Ovarian or Tubal Cancer C56 et C570 * +/- * Carcinose péritonéale C786 * Tumueur maligne secondaire de la plèvre C782, * Tumueur maligne secondaire des ganglions C770 à C779, * Tumueur maligne secondaire du foie C787, * Tumueur maligne secondaire du péritoine C786 Exclusion criteria: * autres causes de : * Carcinose péritonéale C786 * Tumueur maligne secondaire de la plèvre C782, * Tumueur maligne secondaire des ganglions C770 à C779, * Tumueur maligne secondaire du foie C787, * Tumueur maligne secondaire du péritoine C786

What they're measuring

To study the prognostic effect of the volume of activity

Timeframe: at 5 years

Verify that the therapeutic sequence

Timeframe: at 5 years

Trial details

NCT IDNCT05204342

SponsorUniversity Hospital, Montpellier

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-30

View on ClinicalTrials.gov More Ovarian Cancer trials